IP Library Granted Patent US 10,040,825
Granted Patent B2
US 10,040,825 · App. 12/808,930 · Granted Aug 7, 2018

Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof

Inventors: Yee-peng Chan (Bethesda, MD); Christopher Broder (Silver Spring, MD)
Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
C07K14/005A61K39/12C07K16/1027A61K2039/505A61K2039/6031C12N2760/18222C12N2760/18234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,040,825
App. No.
12/808,930
Granted
Aug 7, 2018
Kind
B2
Abstract

This invention relates to soluble forms of F glycoprotein from Hendra and Nipah virus and to compositions comprising soluble forms of F glycoprotein from Hendra and Nipah virus. This invention further relates to soluble oligomers of F glycoprotein from Hendra and Nipah virus. This invention also relates to nucleic acids encoding soluble forms of F glycoprotein from Hendra and Nipah virus. This invention also relates to diagnostic and therapeutic methods using the soluble forms of F glycoprotein from Hendra and Nipah virus. Further, this invention relates to antibodies, including neutralizing antibodies, and to vaccines for the prevention, diagnosis and treatment of infection by Hendra and Nipah viruses.

Claims (6)

1. A soluble polypeptide comprising a soluble antigenic form of a Nipah F glycoprotein, wherein (i) the glycoprotein consists of an amino acid sequence with at least 90 percent sequence identity to amino acids 1 to 488 of SEQ ID NO: 4, (ii) the glycoprotein is fused to a second peptide, and (iii) the second peptide is a trimerization domain which is SEQ ID NO: 10.

2. The soluble polypeptide of claim 1 , wherein the glycoprotein has at least 98 percent identity to amino acids 1 to 488 of SEQ ID NO: 4.

3. The soluble polypeptide of claim 1 , wherein the glycoprotein consists of amino acids 1 to 488 of SEQ ID NO: 4.

4. The soluble polypeptide of claim 1 , wherein the second peptide is located in proximity to the carboxyl terminus of the glycoprotein.

5. A pharmaceutical composition comprising the soluble polypeptide of claim 1 and a pharmaceutically acceptable carrier.

6. A diagnostic kit for detecting a Henipavirus infection in a subject comprising the soluble polypeptide of claim 1 .

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 30, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040466/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: BRODER, CHRISTOPHER C.
To: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
Reel/Frame 027056/0655 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: CHAN, YEE-PENG
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 027056/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 027056/0861 →
Continuity (2)
Provisional Application 61006107 · Dec 19, 2007
Related Publication 20110223172A1 · Sep 15, 2011